Solana Company Q2 FY2020 Earnings Call

· Earnings call transcript and AI-powered summary

  • Revenue: $133,000 for Q2 2020, down from $518,000 in Q2 2019 — a 74% YoY decline driven primarily by COVID-19-related clinic disruptions in Canada.
  • Gross Profit: $69,000 in Q2 2020 vs. $306,000 in Q2 2019.
  • Operating Expenses: Decreased by 38% YoY to $3.8 million from $6.1 million due to cost-cutting initiatives.
  • SG&A Expenses: Down $1.5 million YoY, primarily due to reduced U.S. launch planning costs and lower wages/headcount.
  • R&D Expenses: Down $1 million YoY as PoNS device development was completed in 2019.
  • Canadian Operations: 100% of PoNS-authorized clinics have reopened but are operating at ~30% capacity due to government-mandated limits and patient hesitancy.
  • Key Commercial Development: Addition of 5 new PoNS clinics during the quarter despite challenging environment.
  • Pricing Model Update: Implemented a new patient pricing model to reduce upfront costs and allow installment payments based on response within the first month.
  • Regulatory Progress: De novo submission to FDA for MS indication completed; based on positive clinical studies and real-world evidence used in Health Canada clearance.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good evening, ladies and gentlemen, and welcome to the Second Quarter of Fiscal Year 2020 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed on a listen-only mode. Please note that this conference call is being recorded and that the recording will be made available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management, including statements regarding the impact of COVID-19 pandemic on the company's operations, the success of the company's planned studies and submissions, the future commercialization of the PoNS treatment, expected future clinical and regulatory timelines, the potential receipt of regulatory clearance of the PoNS device in the United States and projected financial results. Phil Deschamps: Thank you very much, operator. And welcome, everyone, to Helius Medical's second quarter of 2020 earnings conference call. I'm joined the call this evening as per usual, by my partner, Joyce LaViscount, our Chief Financial Officer and Chief Operating Officer. Before we start, let me provide you with a quick agenda for today's call. I'll begin by discussing our regulatory strategy in the U.S. and the progress we've made in recent months. Following this discussion, I'll review our second quarter revenue results and update you

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional